Metformin inhibits renal cell carcinoma in vitro and in vivo xenograft (Q39523939)

12 September 2017

Metformin inhibits renal cell carcinoma in vitro and in vivo xenograft (English)

1 reference

12 September 2017

1 reference

1 reference

1 reference

Jun Liu

1

1 reference

12 September 2017

Ming Li

2

1 reference

12 September 2017

Bo Song

3

1 reference

12 September 2017

Chunhong Jia

4

1 reference

12 September 2017

Lichao Zhang

5

1 reference

12 September 2017

Xiaochun Bai

6

1 reference

12 September 2017

Weilie Hu

7

1 reference

12 September 2017

15 June 2011

1 reference

12 September 2017

1 reference

12 September 2017

31

1 reference

12 September 2017

264-270

1 reference

12 September 2017

2

1 reference

12 September 2017

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.01.003

Update on systemic therapies of metastatic renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.01.003

Patient-based strategy for systemic treatment of metastatic renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.01.003

Sorafenib in advanced clear-cell renal-cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.01.003

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.01.003

Metformin and reduced risk of cancer in diabetic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.01.003

Long-term metformin use is associated with decreased risk of breast cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.01.003

Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.01.003

The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.01.003

Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.01.003

Metformin induces unique biological and molecular responses in triple negative breast cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.01.003

Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.01.003

Fibroblast growth factor and insulin-like growth factor differentially modulate the apoptosis and G1 arrest induced by anti-epidermal growth factor receptor monoclonal antibody.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.01.003

Rheb activates mTOR by antagonizing its endogenous inhibitor, FKBP38.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.01.003

Hydrogen peroxide induces G2 cell cycle arrest and inhibits cell proliferation in osteoblasts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.01.003

AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.01.003

Obesity is associated with a higher risk of clear-cell renal cell carcinoma than with other histologies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.01.003

The role of diabetes mellitus in the aetiology of renal cell cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.01.003

The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.01.003

Expression of cyclin D1, D3, E, and p27 in human renal cell carcinoma analysed by tissue microarray

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.01.003

Association of the cyclin D1 gene G870A polymorphism with susceptibility to sporadic renal cell carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.01.003

Specific pattern of LKB1 and phospho-acetyl-CoA carboxylase protein immunostaining in human normal tissues and lung carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.01.003

Histological evaluation of AMPK signalling in primary breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.01.003

The genetic basis of kidney cancer: a metabolic disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.01.003

Activation of the mTOR signaling pathway in renal clear cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.01.003

Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.01.003

10.1016/J.UROLONC.2011.01.003

7 January 2021

Identifiers

DOI

1 reference

12 September 2017

1 reference